Hayes Christopher G.'s Form 4 filing
Verrica Pharmaceuticals Inc. (VRCA) · filed Jul 25, 2023
- Accession no.
- 0001209191-23-043306
- Filed
- Jul 25, 2023
- Trade date
- Jul 21-24, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $163.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hayes Christopher G.CIK 0001805359 | Officer (Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2023 | Common Stock | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 115,714 | Direct | |
| Jul 24, 2023 | Common Stock | SSaleDisposed | −33,789 | $4.83 | −$163,200.87 | 81,925 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.